Breadcrumb

[A15-07] Dulaglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Overview

Overview

Commission: Commission awarded on 2015-02-02 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 661 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A15-22] Dulaglutide (Addendum to Commission A15-07)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2015-05-04 Extract of dossier assessment 661 kBPDFdownload file
2015-05-04 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2015-07-16 A G-BA decision was published.

G-BA documents on this decision

Press releases

2015-05-04 Dulaglutide in type 2 diabetes: hint of an added benefit in combination with short-acting insulin



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close